/ Print /

Hospitals & Providers

Value-based payment update: Where we are and who is most successful
Value-based payment update: Where we are and who is most successfulWhile these types of programs have been in place for several years, it can be difficult to gauge who is using them and how, and whether they are achieving their intended goal.
Ten ways hospitals can manage rising drug costs
Ten ways hospitals can manage rising drug costsFluctuations in drug pricing and medication shortages are among the reasons for rising drug prices. Learn how you can protect your hospital’s bottom line.
Guided therapy can improve antibiotic resistanceResearchers share surprising findings about PCT-guided therapy in antibiotic management in patients with respiratory infections.
Five approaches to effective cancer care managementManaging the care for members with cancer is unlike managing care for other chronic diseases. Here’s five ways to better care for cancer patients.
Risk-contract engagement strategies should differ for independent, employed docsIf your organization is managing a risk-based contract, you are likely working hard to engage physicians. But are you modifying those efforts based on whether physicians are independent or employed? Here’s why you should.
Four oncology treatment advances to watch
Four oncology treatment advances to watchExperts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
Genetic testing: 3 things managed healthcare executives should knowA new survey on genetic testing has surprisingly results on consumer acceptance and impact for healthcare executives.
Top 5 consumer health concernsA new survey from consumer health companies has revealing findings about American health and well-being.
Here’s a more effective way to test for HPVA Kaiser Permanente study found that a new way to test for HPV has the potential to increase efficiency and decrease waste.
CMS plan to slash 340B payments under fire by hospitalsHere are four ways CMS’ final rule related to the 340B Drug Pricing Program could affect the healthcare industry.